Primary cell lines and 3D model systems can provide in vitro assays of high physiological relevance, but the availability of cells and/or suitable assay technologies limit their application to large scale screening. The use of differentiated stem cells provides a disease- and tissue type-relevant alternative, particularly for investigating disease indications where there is a clear genetic causal link.

View this webinar to learn how human embryonic stem cells were used to develop and validate a 384-well format assay and subsequently conduct a high-throughput screen to identify compounds that modulate mutant protein levels in a neurodegenerative disease, demonstrating how stem cells balance biological relevance and throughput.


  • David Cronk, CBiol, MRSB, Director, High-Throughput Screening Services, Charles River


  • Bethany Nancolas, PhD, Senior Scientist, Biology, Charles River